[go: up one dir, main page]

Jiang et al., 2022 - Google Patents

Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation

Jiang et al., 2022

Document ID
14162248003607783200
Author
Jiang H
Zhang Y
Wu Y
Cheng J
Feng S
Wang J
Wang X
Cheng M
Publication year
Publication venue
Biochemical and Biophysical Research Communications

External Links

Snippet

Abstract Flavivirus, such as Dengue Virus (DENV) and Zika virus (ZIKV), infects millions of people and cause the death of thousands of people every year. Despite many efforts, there is no approved anti-flaviviral treatment available. In particular, some antiflavivirus …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Similar Documents

Publication Publication Date Title
Guedes et al. Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants
KR101164070B1 (en) Hepatitis C virus NS5B polymerase inhibitor binding pocket
Frick et al. Molecular basis for ADP-ribose binding to the Mac1 domain of SARS-CoV-2 nsp3
Sacramento et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
Mirza et al. Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study
Aggarwal et al. Evaluation of antiviral activity of piperazine against Chikungunya virus targeting hydrophobic pocket of alphavirus capsid protein
Dong et al. Flavivirus methyltransferase: a novel antiviral target
Chang et al. Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay
Bahl et al. Gene flow and competitive exclusion of avian influenza A virus in natural reservoir hosts
Kumar et al. Mechanistic insights into Zika virus NS3 helicase inhibition by epigallocatechin-3-gallate
Jiang et al. Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation
Liang et al. Binding mechanism of inhibitors to SARS-CoV-2 main protease deciphered by multiple replica molecular dynamics simulations
Choi et al. The structure of bovine viral diarrhea virus RNA-dependent RNA polymerase and its amino-terminal domain
Mirza et al. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies
Menéndez-Arias et al. Antiviral agents: structural basis of action and rational design
Milani et al. Flaviviral methyltransferase/RNA interaction: structural basis for enzyme inhibition
ul Qamar et al. Potential of plant alkaloids as dengue ns3 protease inhibitors: Molecular docking and simulation approach
Wichapong et al. Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction
Bhosale et al. Screening of phytoconstituents of Andrographis paniculata against various targets of Japanese encephalitis virus: An in-silico and in-vitro target-based approach
Akaberi et al. Identification of a C2-symmetric diol based human immunodeficiency virus protease inhibitor targeting Zika virus NS2B-NS3 protease
Samdani et al. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening
Zia et al. Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease
Hossain et al. Therapeutic potential of antiviral peptides against the NS2B/NS3 protease of Zika virus
Bullard et al. Murine efficacy and pharmacokinetic evaluation of the flaviviral NS5 capping enzyme 2-thioxothiazolidin-4-one inhibitor BG-323
Otsuka et al. High throughput screening for SARS-CoV-2 helicase inhibitors